THE BELGIAN OPHTHALMIC ASSOCIATIONS
View abstract
Cet abstract a été assigné à session OB Free papers: Medical retina
| Titre | FRO: AAV mediated SOCS1 gene expression in ARPE cells in an immune rejection model of xeno-graft for AMD diseases |
| Abstract Nr. | 248 |
| But | AMD is one of the most important blinding disorders in western countries for elderly people. It is represented in 20% of cases by new vessels raising from the choroid to invade the subretinal space. Even with anti-VEGF treatments, some patients evolve to a big fibrinous macular scar. One treatment in those cases would be to remove this membrane and to graft some RPE cells that should not be recognised by the immune system. In our laboratory, SOCS1 gene has been shown to allow a strong reduction of MHCII expression in IFN gamma stimulated ARPE cells. |
| Méthodes | At day 0, ARPE cells will be infected with AAV2-CAG-SOCS1 and -eGFP or AAV2-CAG-eGFP alone (AAV control) in order to obtain a coefficient of 80-90% of gene expression. At day 2, cells will be injected in the subretinal space of Wistar rats. Rat eyes will be examined by using a fluorescein angiography camera and pictures will be tooked on a daily basis in order to follow the subretinal graft progression. Animals will be sacrificed at 7 weeks and eyes removed for fixation and cryoprotection prior to mounting and freezing at -80°C. 10µm sections of eyes will be obtained at cryostat and different immunofluorescence on slides will be performed. |
| Résultats | AMD is a severe blinding disease in western countries. Immune rejection is one of the last limitations for RPE cells transplantation in sub-retinal space for end-stage presentations. We herein propose to reduce MHCII expression on ARPE and slow growing hRPE cells by SOCS1 gene transfer prior to their injection in the subretinal space of Wistar rats. |
| Conclusion | Thus, we will investigate if immune rejection in the subretinal space is mainly due to MHCII expression on RPE cells or MHCI. Of course, such results would be of a great interest for treatment of AMD macular scars. |
Auteur 1
| Nom | KOCH |
| Initiales | P |
| Institut | CHU St-Pierre |
| Ville | Brussels |